Singapore-based biopharmaceutical firm Hilleman Laboratories (Hilleman Labs) has implemented RISE with SAP to enhance savings, speed, and decision-making across the organisation through the integration of data, intelligent technology, and enterprise resource planning (ERP) software on the SAP digital platform.
In October, Singaporean Prime Minister Lee Hsien Loong announced that the city-state will donate $7.9 million in medical supplies to a regional reserve on behalf of ASEAN’s collective effort to lay the groundwork for public health emergencies in the future. The article by The Strait Times also indicated that Singapore co-chairs the Friends of Covax Facility with Switzerland to foster vaccine multilateralism. Supported by the World Health Organization, the program intends to deliver vaccinations to people in low-income countries.
Underscoring the nation’s endeavour to provide access to quality healthcare and improve living conditions for all, Hilleman Labs was established in Singapore as a premier biopharmaceutical company focused on developing vaccines to address unmet health needs in poor countries. Through an equal joint-venture partnership between Merck Sharp & Dohme Corp. (MSD) and Wellcome Trust, the company was founded in 2011 and has since been gearing towards tackling preventable diseases that are widespread in low and middle-income nations.
With innovation as one of its core values, Hilleman Labs believes in the importance of leveraging technological advancements to obtain meaningful insights from different data sources, strengthen stakeholder collaboration, and facilitate vaccine development while maintaining industry compliance. Recently, it has chosen SAP’s Business Transformation as a Service (BTaaS) offering RISE with SAP to accelerate digital transformation and help discover opportunities in value creation among strategic IT projects.
Hilleman Labs is one of numerous small and medium-sized enterprises (SMEs) across Southeast Asia that have already embarked on their intelligent enterprise journeys to help streamline business processes, break down data silos, and gain supply chain visibility.
Hilleman Labs Integrates Data and ERP Software on SAP Digital Platform
Detailing more about the latest partnership, Eileen Chua, Managing Director at SAP Singapore, explained:
“By adopting a modern, innovative cloud solution such as RISE with SAP, Hilleman Labs has been able to embark on its mission to holistically transform into an intelligent enterprise and stay ahead of their industry. Their vaccine development efforts are now backed by a strong digital core that aims to offer greater visibility, efficiency, and agility while achieving business outcomes and supporting their mission to improve global health.”
Supported by SAP Partner ABeam Consulting Singapore, the RISE with SAP implementation was completed in less than three months. By breaking down silos and integrating data, intelligent technologies, and ERP software on a single SAP digital platform and data model, the new infrastructure is anticipated to deliver faster time to value and boost savings, speed, and decision-making across the company.
According to Hilleman Labs, the adoption of the BTaas offering aims to:
- Enable the solution to build a flexible digital infrastructure that connects and expands with other applications.
- Embed new technologies including artificial intelligence (AI), machine learning (ML), and advanced analytics capabilities into the system.
- Allow scientists and medical researchers to conduct real-time analysis of process development and analytics, as well as clinical and genomics data from various sources.
- Create patient cohorts and quickly assess the feasibility of clinical trials on a local level.
- Promote collaboration and gain access to SAP Business Network which includes SAP’s asset intelligence, supplier, and logistics networks.
Also commenting on the SAP deployment project, Dr. Raman Rao, Chief Executive Officer at Hilleman Labs, highlighted:
“With the adoption of RISE with SAP, our goal is to become more agile, innovative, and productive as we accelerate our efforts to develop new vaccines and unlock new vaccine development methods that could have significant impact globally.”
